Johnson & Johnson (JNJ) Hit With $8B Punitive Damage Verdict Related to Male Breast Growth Linked to RISPERDAL

Johnson & Johnson (NYSE: JNJ) is lower after the company was hit with an $8 billion punitive damages verdict in Pennsylvania for ignoring the risks that its antipsychotic drug, RISPERDAL, could lead to male breast growth in adolescent children.

Johnson & Johnson believes the verdict was “grossly disproportionate with the initial compensatory award in this case, and the company is confident it will be overturned."

Shares of JNJ are down 1.8% in pre-open trading Wednesday.

You May Also Be Interested In

• US DoJ to Decide by as Soon as Late May Whether Boeing Violated Prosecution Deal - Reuters
• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• Tuta Mail Files Google Complaint Under EU Tech Rules - Reuters